In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on BioNTech SE (BNTX - Research Report), with a price target of $272.00. The company's shares closed last Friday at $150.91.Burns covers the Healthcare sector, focusing on stocks such as BioNTech SE, Portage Biotech Inc, and Springworks Therapeutics. According to TipRanks, Burns has an average return of -16.2% and a 27.20% success rate on recommended stocks. In addition to H.C. Wainwright, BioNTech SE also received a Buy from Berenberg Bank's Zhiqiang Shu in a report issued on September 8. However, on the same day, Deutsche Bank maintained a Hold rating on BioNTech SE (NASDAQ: BNTX).
https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-biontech-se-bntx?utm_source=advfn.com&utm_medium=referral
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more BioNTech Charts.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more BioNTech Charts.